A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19
Latest Information Update: 21 May 2021
At a glance
- Drugs Anakinra (Primary) ; Aprotinin (Primary) ; Enoxaparin sodium; Nadroparin calcium
- Indications COVID 2019 infections
- Focus Proof of concept; Therapeutic Use
- Acronyms DAWN AntiCo
- 21 May 2021 Status changed from recruiting to completed.
- 16 Apr 2021 New trial record